Details of the Drug
General Information of Drug (ID: DMX0VQN)
| Drug Name |
NSC-73410
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
NSC-73410; CHEMBL435920; 5138-23-8; NSC73410; Alizarine Saphirol SE; NCIOpen2_008926; SCHEMBL10706301; DTXSID50274577; ZINC3846907; 4,8-diamino-1,5-dihydroxy-9,10-dioxoanthracene-2-sulfonic acid; AC1L2850; BDBM50195862; 2-Anthracenesulfonic acid,8-diamino-9,10-dihydro-1,5-dihydroxy-9,10-dioxo-
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 350.31 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 0.6 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 5 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 9 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


